Syndax Pharmaceuticals Inc. - news published 246 - readings 2.254

BACK

Syndax Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

17.03.2025

Syndax Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

06.03.2025

Syndax Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ Syndax Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) __ ...

04.03.2025

Syndax Pharmaceuticals Inc.

Syndax Fourth Quarter 2024 Conference Call

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Syndax Pharmaceuticals Inc. published this content on March 03, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 03, 2025 at 12:52:22.011 .

03.03.2025

Syndax Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon current b ...

03.03.2025

Syndax Pharmaceuticals Inc.

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Form 8-K)

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch - • Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivot ...

03.03.2025